Table 1.
Patient characteristics, chimerism follow-up and outcome. ALL: Acute Lymphoblastic Leukemia; AML: Acute Myeloid Leukemia; MDS/MPN: Myelodysplastic Syndrome/Myeloproliferative Neoplasm; NHL: Non-Hodgkin Lymphoma.
| Total–n | 57 |
|---|---|
| Sex Female—n (%) | 20 (35) |
| Age, years—median (range) | 46 (6–66) |
| Diagnosis—n (%) | |
| - AML | 42 (74) |
| - ALL | 10 (18) |
| - MDS/MPN | 3 (5) |
| - NHL | 2 (3) |
| Time to switch, months—median (range) | 13 (1–48) |
| qPCR performed in PB—n (%) | 57 (100) |
| Number of PB samples—mean (range) | 6.12 (1–16) |
| Recipient DNA 0.1–1% in PB—n (%) | 4 (7) |
| qPCR performed in BM—n (%) | 46 (81) |
| Number of BM samples—mean (range) | 2.14 (0–9) |
| Recipient DNA 0.1–1% in BM—n (%) - One sample - More than one sample |
27 (59) 11 (24) 16 (35) |
| Molecular MRD marker—n (%) | |
| - None | 13 (23) |
| - WT1 | 23 (40) |
| - NPM1 | 12 (21) |
| - Other | 10 (18) |
| Positive molecular MRD marker—n (%) | 2 (5) |
| Relapse—n (%) | 1 (2) |
| Follow-up—median (range) | 32 (9–67) |